LONDON, UK: Ashington Innovation (LSE:ASHI), a SPAC that focuses on technology businesses, has announced that it has signed a non-binding term sheet to acquire Cell Therapy Limited, a clinical stage biotechnology firm with a portfolio of patented cellular medicines. Cell Therapy is developing novel therapies for heart failure, based on its proprietary technology that uses…